Tag: Kinase inhibitors

Affecting thousands, myelofibrosis is a serious blood cancer characterized by an overactive Janus kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) signaling pathway. Ruxolitinib is a targeted therapy that addresses this core issue, providing significant symptom relief and improving patient outcomes. The mechanism of action of ruxolitinib in myelofibrosis centers on potent inhibition of key Janus kinases, altering disease progression.

In 2001, the U.S. Food and Drug Administration (FDA) approved imatinib (brand name Gleevec), marking a monumental shift in cancer treatment as it was the first rationally designed kinase inhibitor to directly target a specific cancer-causing protein. Its approval opened the door to a new era of precision medicine, demonstrating that targeted therapy could be a safe and highly effective alternative to conventional chemotherapy.